BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013;35:1282-303. [PMID: 24054705 DOI: 10.1016/j.clinthera.2013.08.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Hicks MJ, Chiuchiolo MJ, Ballon D, Dyke JP, Aronowitz E, Funato K, Tabar V, Havlicek D, Fan F, Sondhi D, Kaminsky SM, Crystal RG. Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLoS One 2016;11:e0162978. [PMID: 27711187 DOI: 10.1371/journal.pone.0162978] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
2 Abumustafa W, Zamer BA, Khalil BA, Hamad M, Maghazachi AA, Muhammad JS. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies. Biomed Pharmacother 2021;145:112368. [PMID: 34794114 DOI: 10.1016/j.biopha.2021.112368] [Reference Citation Analysis]
3 Zhang B, Liu Z, Xia S, Liu Q, Gou S. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Eur J Med Chem 2021;216:113300. [PMID: 33640672 DOI: 10.1016/j.ejmech.2021.113300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Low HB, Zhang Y. Regulatory Roles of MAPK Phosphatases in Cancer. Immune Netw 2016;16:85-98. [PMID: 27162525 DOI: 10.4110/in.2016.16.2.85] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 14.5] [Reference Citation Analysis]
5 Lee SL, Dempsey-hibbert NC, Vimalachandran D, Wardle TD, Sutton P, Williams JHH. Targeting Heat Shock Proteins in Colorectal Cancer. In: Asea AA, Almasoud NN, Krishnan S, Kaur P, editors. Heat Shock Protein-Based Therapies. Cham: Springer International Publishing; 2015. pp. 345-79. [DOI: 10.1007/978-3-319-17211-8_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ma B, Wells A. The mitogen-activated protein (MAP) kinases p38 and extracellular signal-regulated kinase (ERK) are involved in hepatocyte-mediated phenotypic switching in prostate cancer cells. J Biol Chem 2014;289:11153-61. [PMID: 24619413 DOI: 10.1074/jbc.M113.540237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
7 Cheng X, Chen H. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther 2014;7:1689-704. [PMID: 25285017 DOI: 10.2147/OTT.S66502] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
8 Cristofari C, Rigo R, Greco ML, Ghezzo M, Sissi C. pH-driven conformational switch between non-canonical DNA structures in a C-rich domain of EGFR promoter. Sci Rep 2019;9:1210. [PMID: 30718769 DOI: 10.1038/s41598-018-37968-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Wu L, Leng D, Cun D, Foged C, Yang M. Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. J Control Release 2017;260:78-91. [PMID: 28527735 DOI: 10.1016/j.jconrel.2017.05.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
10 Zhang Y, Tortorella MD, Liao J, Qin X, Chen T, Luo J, Guan J, Talley JJ, Tu Z. Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents. ACS Med Chem Lett 2015;6:1086-90. [PMID: 26487917 DOI: 10.1021/acsmedchemlett.5b00286] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
11 Liang Y, Zhang T, Zhang J. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy. Pharmacol Res 2020;161:105164. [PMID: 32846211 DOI: 10.1016/j.phrs.2020.105164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Ozturk N, Ozturk D, Kavakli IH, Okyar A. Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy. Int J Mol Sci 2017;18:E2168. [PMID: 29039812 DOI: 10.3390/ijms18102168] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
13 Greco ML, Kotar A, Rigo R, Cristofari C, Plavec J, Sissi C. Coexistence of two main folded G-quadruplexes within a single G-rich domain in the EGFR promoter. Nucleic Acids Res 2017;45:10132-42. [PMID: 28973461 DOI: 10.1093/nar/gkx678] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
14 Koehler Leman J, Bonneau R. A Novel Domain Assembly Routine for Creating Full-Length Models of Membrane Proteins from Known Domain Structures. Biochemistry 2018;57:1939-44. [PMID: 29185719 DOI: 10.1021/acs.biochem.7b00995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
15 Yan JJ, Liao JZ, Lin JS, He XX. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems. Tumour Biol. 2015;36:55-67. [PMID: 25424700 DOI: 10.1007/s13277-014-2855-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
16 Lee YM, Sun YH. Maintenance of glia in the optic lamina is mediated by EGFR signaling by photoreceptors in adult Drosophila. PLoS Genet 2015;11:e1005187. [PMID: 25909451 DOI: 10.1371/journal.pgen.1005187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
17 Bao Z, Chen K, Krepel S, Tang P, Gong W, Zhang M, Liang W, Trivett A, Zhou M, Wang JM. High Glucose Promotes Human Glioblastoma Cell Growth by Increasing the Expression and Function of Chemoattractant and Growth Factor Receptors. Transl Oncol 2019;12:1155-63. [PMID: 31207546 DOI: 10.1016/j.tranon.2019.04.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
18 Garousi J, Andersson KG, Mitran B, Pichl ML, Ståhl S, Orlova A, Löfblom J, Tolmachev V. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. Int J Oncol 2016;48:1325-32. [PMID: 26847636 DOI: 10.3892/ijo.2016.3369] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
19 Li YQ, Liu YS, Ying XW, Zhou HB, Wang Z, Wu SC, Yan JP, Jing YT, Yang Y. Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro. Biotechnol Prog 2018;34:196-205. [PMID: 28960861 DOI: 10.1002/btpr.2564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Ying HQ, Wang F, Chen XL, He BS, Pan YQ, Jie C, Liu X, Cao WJ, Peng HX, Lin K, Wang SK. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. Oncotarget 2015;6:28071-83. [PMID: 26363448 DOI: 10.18632/oncotarget.4872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Rohilla S, Awasthi R, Mehta M, Chellappan DK, Gupta G, Gulati M, Singh SK, Anand K, Oliver BG, Dua K, Dureja H. Preparation and Evaluation of Gefitinib Containing Nanoliposomal Formulation for Lung Cancer Therapy. BioNanoSci . [DOI: 10.1007/s12668-022-00938-6] [Reference Citation Analysis]
22 Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. Onco Targets Ther 2016;9:5427-37. [PMID: 27621656 DOI: 10.2147/OTT.S114039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Jimenez-luna C, Prados J, Ortiz R, Melguizo C, Torres C, Caba O. Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology 2016;50:836-48. [DOI: 10.1097/mcg.0000000000000623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 Wang Y, Wang M, Wang Q, Geng Z, Sun M. Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 2017;8:29406-15. [PMID: 28107192 DOI: 10.18632/oncotarget.14707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lee JM, Lee SH, Hwang JW, Oh SJ, Kim B, Jung S, Shim SH, Lin PW, Lee SB, Cho MY, Koh YJ, Kim SY, Ahn S, Lee J, Kim KM, Cheong KH, Choi J, Kim KA. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene 2016;35:4437-46. [PMID: 26853467 DOI: 10.1038/onc.2015.514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
26 Duffy MJ. Personalized treatment for patients with colorectal cancer: role of biomarkers. Biomark Med. 2015;9:337-347. [PMID: 25808438 DOI: 10.2217/bmm.15.3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Lin P, An F, Xu X, Zhao L, Liu L, Liu N, Wang P, Liu J, Wang L, Li M. Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice. Biochemical and Biophysical Research Communications 2015;460:362-7. [DOI: 10.1016/j.bbrc.2015.03.039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
28 Narayanan D, Gani OABSM, Gruber FXE, Engh RA. Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. J Cheminform 2017;9:43. [PMID: 29086093 DOI: 10.1186/s13321-017-0229-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
29 Morra F, Merolla F, Picardi I, Russo D, Ilardi G, Varricchio S, Liotti F, Pacelli R, Palazzo L, Mascolo M, Celetti A, Staibano S. CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC. Cancers (Basel) 2019;11:E1582. [PMID: 31627329 DOI: 10.3390/cancers11101582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
30 Zhang X, Liu K, Zhang T, Wang Z, Qin X, Jing X, Wu H, Ji X, He Y, Zhao R. Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway. Oncotarget. 2017;8:1541-1554. [PMID: 27903975 DOI: 10.18632/oncotarget.13652] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
31 Iglesias R, Koria P. Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0708-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
32 Blumrich EM, Kadam R, Dringen R. The Protein Tyrosine Kinase Inhibitor Tyrphostin 23 Strongly Accelerates Glycolytic Lactate Production in Cultured Primary Astrocytes. Neurochem Res 2016;41:2607-18. [PMID: 27278759 DOI: 10.1007/s11064-016-1972-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C, Stoecklein NH, Knoefel WT, Angenendt S, Hauch S. Characterization of different CTC subpopulations in non-small cell lung cancer. Sci Rep. 2016;6:28010. [PMID: 27302574 DOI: 10.1038/srep28010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
34 Guan L, Tan J, Li H, Jin X. Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data. Gene 2018;647:205-12. [DOI: 10.1016/j.gene.2017.12.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
35 Müller CB, De Bastiani MA, Becker M, França FS, Branco MA, Castro MA, Klamt F. Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer. Oncotarget 2015;6:3531-9. [PMID: 25784483 DOI: 10.18632/oncotarget.3471] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
36 Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L. Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. Oncotarget 2016;7:74097-106. [PMID: 27765917 DOI: 10.18632/oncotarget.12272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wen Q, Wang W, Chu S, Luo J, Chen L, Xie G, Xu L, Li M, Fan S. Flot-2 Expression Correlates with EGFR Levels and Poor Prognosis in Surgically Resected Non-Small Cell Lung Cancer. PLoS One 2015;10:e0132190. [PMID: 26161893 DOI: 10.1371/journal.pone.0132190] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
38 Liu X, Song B, Li S, Wang N, Yang H. Identification and functional analysis of the risk microRNAs associated with cerebral low-grade glioma prognosis. Mol Med Rep 2017;16:1173-9. [PMID: 28586047 DOI: 10.3892/mmr.2017.6705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
39 Jia Z. Role of integrin-linked kinase in drug resistance of lung cancer. Onco Targets Ther 2015;8:1561-5. [PMID: 26150729 DOI: 10.2147/OTT.S81447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
40 Li C, Yao L, Gong J, Pang H, Shan Q, Wang Z, Lu J, Wang Z. Efficacy of Gefitinib Combined with 125I Radioactive Particles in the Treatment of Transplanted Lung Cancer Tumors in Nude Mice. Cardiovasc Intervent Radiol 2020;43:1364-70. [PMID: 32607617 DOI: 10.1007/s00270-020-02550-1] [Reference Citation Analysis]
41 Chang WC, Wu SL, Huang WC, Hsu JY, Chan SH, Wang JM, Tsai JP, Chen BK. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget 2015;6:7741-57. [PMID: 25797258 DOI: 10.18632/oncotarget.3482] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
42 Foroughi S, Tie J, Gibbs P, Burgess AW. Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer. Growth Factors 2019;37:209-25. [DOI: 10.1080/08977194.2019.1703702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Zhang B, Xu Z, Liu Q, Xia S, Liu Z, Liao Z, Gou S. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation. Bioorg Chem 2021;117:105420. [PMID: 34655841 DOI: 10.1016/j.bioorg.2021.105420] [Reference Citation Analysis]
44 Bergamo A, Dyson PJ, Sava G. The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. Coordination Chemistry Reviews 2018;360:17-33. [DOI: 10.1016/j.ccr.2018.01.009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 15.3] [Reference Citation Analysis]
45 Romagnoli R, Prencipe F, Oliva P, Baraldi S, Baraldi PG, Schiaffino Ortega S, Chayah M, Kimatrai Salvador M, Lopez-Cara LC, Brancale A, Ferla S, Hamel E, Ronca R, Bortolozzi R, Mariotto E, Mattiuzzo E, Viola G. Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. J Med Chem 2019;62:1274-90. [PMID: 30633509 DOI: 10.1021/acs.jmedchem.8b01391] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
46 Kim YE, Kwon S, Wu G, Kim D, Park BK, Park JA, Choi KC, Kim DS, Kwon HJ, Lee Y. Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model. Oncotarget 2014;5:8402-15. [PMID: 25268742 DOI: 10.18632/oncotarget.2311] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
47 Jhaveri DT, Zheng L, Jaffee EM. Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol 2014;41:559-75. [PMID: 25440603 DOI: 10.1053/j.seminoncol.2014.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
48 Ciechomska IA, Gielniewski B, Wojtas B, Kaminska B, Mieczkowski J. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide. Exp Mol Med 2020;52:1326-40. [PMID: 32788653 DOI: 10.1038/s12276-020-0479-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med 2014;12:203. [PMID: 25369798 DOI: 10.1186/s12916-014-0203-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
50 Aguilera JR, Venegas V, Oliva JM, Sayagués MJ, de Miguel M, Sánchez-alcázar JA, Arévalo-rodríguez M, Zaderenko AP. Targeted multifunctional tannic acid nanoparticles. RSC Adv 2016;6:7279-87. [DOI: 10.1039/c5ra19405a] [Cited by in Crossref: 15] [Article Influence: 2.5] [Reference Citation Analysis]